CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

poly-iclc

Small moleculeexperimental

Clinical trial activity

111 trials · 100 clinical orgs · 0 marketing orgs

Phase 1
86
Phase 2
45
Phase 3
0
Phase 4
1

Earliest trial started Sep 1, 2002 (NCT00094003)

Timeline

2000s

  1. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2002

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • hiltonol
  • hiltonol
  • hiltonol
  • jnj-43260295
  • muc1 peptide-poly-iclc adjuvant vaccine
  • oncovir
  • p.i.c.l.c.
  • poly iclc
  • poly iclc
  • poly iclc
  • poly-iclc
  • poly-iclc
  • poly-iclc
  • poly iclc, sodium salt
  • polyriboinosinic-polyribocytidylic acid-polylysine carboxymethylcellulose
  • polyriboinosinic-polyribocytidylic acid-polylysine carboxymethylcellulose

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07300475Phase 1Mar 31, 2026Washington University in St. Louis
NCT07113106Phase 1/Phase 2 (Phase 2)Jun 18, 2025Government of France, Institut National de la Santé Et de la Recherche Médicale, France
NCT06665646Phase 1Feb 4, 2025National Institute of Allergy and Infectious Diseases (NIAID)
NCT06342908Phase 1Dec 8, 2024University of California, Los Angeles
NCT06529822Phase 1Nov 30, 2024Natera, Inc., Washington University in St. Louis
NCT06411691Phase 1Nov 4, 2024Agenus Inc., Department of Defense, Johns Hopkins University, National Cancer Institute (NCI), National Institutes of Health (NIH)
NCT06472661Early Phase 1 (Phase 1)Sep 30, 2024Theraclion, University of Virginia
NCT06218303Phase 1Feb 7, 2024Breast Cancer Research Foundation, University of Pittsburgh
NCT06064279Phase 1/Phase 2 (Phase 2)Feb 5, 2024Department of Veteran Affairs, Oncovir, Inc.
NCT06343077Phase 2Jan 16, 2024Icahn School of Medicine at Mount Sinai, Oncovir, Inc.
NCT05457959Phase 1Jan 1, 2023University of California, Los Angeles
NCT05283109Phase 1Nov 30, 2022Duke University, National Cancer Institute (NCI)
NCT06614140Phase 1/Phase 2 (Phase 2)Nov 24, 2022Seqker Biosciences, Inc.
NCT05557240N/ASep 13, 2022Huazhong University of Science and Technology
NCT05098210Phase 1Apr 1, 2022University of Washington
NCT04799431Phase 1Dec 31, 2021Incyte, Johns Hopkins University
NCT05111353Phase 1Dec 31, 2021Leidos, National Cancer Institute (NCI), Washington University in St. Louis
NCT04777708Early Phase 1 (Phase 1)Oct 13, 2021Highlight Therapeutics, Merck, University of California, Los Angeles
NCT05281926Phase 1Oct 1, 2021National Taiwan University
NCT05010200Phase 1Sep 30, 2021Icahn School of Medicine at Mount Sinai
Showing 20 of 111 trials
Page 1 / 6

Organizations

Research & Development (100)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Cancer Institute (NCI)Government21522002
Oncovir, Inc.For profit18222006
Icahn School of Medicine at Mount SinaiAcademic/Hospital141022010
University of PittsburghAcademic/Hospital8732006
University of VirginiaAcademic/Hospital7622012
Washington University in St. LouisAcademic/Hospital7712015
Celldex TherapeuticsFor profit6222009
National Institutes of Health (NIH)Government6032008
Johns Hopkins UniversityAcademic/Hospital5522002
State University of New York, BuffaloAcademic/Hospital5422013
University of California, Los AngelesAcademic/Hospital5522010
University of California, San FranciscoAcademic/Hospital5222002
Ludwig Institute for Cancer ResearchAcademic/Hospital4222008
Medical University of South CarolinaAcademic/Hospital4122011
MerckFor profit4022016
University of PennsylvaniaAcademic/Hospital4322006
Cancer Research InstituteAcademic/Hospital3022010
Emory UniversityAcademic/Hospital3012010
Harvard UniversityAcademic/Hospital3312014
National Institute of Allergy and Infectious Diseases (NIAID)Government3222008
100 organizations
Page 1 / 5